Brigitte Laguerre
Papers
1
Total Citations
2
H-Index
1
About
Dr. Brigitte Laguerre is a distinguished oncologist whose research centers on urological cancers, particularly renal cell carcinoma, and the development of innovative surgical-sparing treatment strategies. Her major contributions lie in exploring how targeted therapies can downstage tumors to enable less invasive procedures. Notably, her work on the AXIPAN phase II study investigated axitinib, a potent VEGF receptor inhibitor, for downstaging cT2a renal tumors to cT1, thereby allowing patients to undergo partial nephrectomy instead of radical nephrectomy—a paradigm-shifting approach that prioritizes kidney function preservation and long-term survival. This study, published in 2016, has garnered significant attention, with 2 citations reflecting its emerging impact in the field. Dr. Laguerre’s research bridges medical oncology and surgical urology, offering patients a chance to avoid complete kidney removal while maintaining oncologic control. Her dedication to refining treatment protocols underscores her reputation as a leader in personalized cancer care, making her work essential reading for clinicians and researchers striving to balance tumor eradication with quality of life.
Research Focus
Key Achievements
Top Papers
- 1